###begin article-title 0
###xml 90 97 <span type="species:ncbi:9606">Patient</span>
Protein Aggregation and Protein Instability Govern Familial Amyotrophic Lateral Sclerosis Patient Survival
###end article-title 0
###begin p 1
###xml 642 649 <span type="species:ncbi:9606">patient</span>
The nature of the "toxic gain of function" that results from amyotrophic lateral sclerosis (ALS)-, Parkinson-, and Alzheimer-related mutations is a matter of debate. As a result no adequate model of any neurodegenerative disease etiology exists. We demonstrate that two synergistic properties, namely, increased protein aggregation propensity (increased likelihood that an unfolded protein will aggregate) and decreased protein stability (increased likelihood that a protein will unfold), are central to ALS etiology. Taken together these properties account for 69% of the variability in mutant Cu/Zn-superoxide-dismutase-linked familial ALS patient survival times. Aggregation is a concentration-dependent process, and spinal cord motor neurons have higher concentrations of Cu/Zn-superoxide dismutase than the surrounding cells. Protein aggregation therefore is expected to contribute to the selective vulnerability of motor neurons in familial ALS.
###end p 1
###begin title 2
Author Summary
###end title 2
###begin title 3

###end title 3
###begin p 4
###xml 661 669 <span type="species:ncbi:9606">patients</span>
###xml 746 754 <span type="species:ncbi:9606">patients</span>
###xml 1172 1180 <span type="species:ncbi:9606">patients</span>
###xml 1274 1281 <span type="species:ncbi:9606">patient</span>
###xml 1359 1367 <span type="species:ncbi:9606">patients</span>
###xml 1474 1481 <span type="species:ncbi:9606">patient</span>
Amyotrophic lateral sclerosis (ALS), also known in America as Lou Gehrig's disease, is a fatal neurodegenerative disease with no effective treatment. Paralysis occurs as the result of the death of cells that connect the brain to various muscles, namely, the motor neurons of the brain and spinal cord. Ninety percent of ALS is sporadic and of unknown cause. A landmark discovery in ALS research was that mutations in the gene coding for Cu/Zn-superoxide dismutase cause at least 2% of ALS, and researchers have since discovered at least 119 such mutations. Neurologists also discovered that different mutations have remarkably different prognoses. For example, patients with the A4V mutation survive an average of 1 year after diagnosis, whereas patients with the H46R mutation survive an average of 18 years. Biochemists discovered that different mutations result in remarkably different physical properties, for example, stability of Cu/Zn-superoxide dismutase. In this article we apply an algorithm that predicts how fast a given Cu/Zn-superoxide dismutase will aggregate (stick to other proteins) and demonstrate that faster aggregation relates to faster death of ALS patients. We also demonstrate that loss of Cu/Zn-superoxide dismutase stability relates to faster ALS patient death. Our findings imply that aggregation of unfolded SOD1 is toxic for ALS patients, and in fact accounts for 69% of the variability in mutant Cu/Zn-superoxide-dismutase-linked familial ALS patient survival times.
###end p 4
###begin p 5
Increased protein aggregation and decreased protein stability are shown to be central to familial amyotrophic lateral sclerosis etiology.
###end p 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b001">1</xref>
###xml 307 308 307 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b002">2</xref>
###xml 309 310 309 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b004">4</xref>
###xml 499 500 499 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b001">1</xref>
###xml 501 502 501 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b005">5</xref>
###xml 491 497 <span type="species:ncbi:9606">humans</span>
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease with roughly 10% of the cases being inherited or familial [1]. The cause of sporadic ALS (sALS) is unknown while familial ALS (fALS) is known to be caused by mutations in six different genes and six different chromosomal loci [2-4]. One of these genes encoding Cu/Zn-superoxide dismutase (SOD1) was found to associate with 20% of fALS, and at least 119 fALS-associated SOD1 mutations have been characterized in humans [1,5].
###end p 7
###begin p 8
###xml 69 70 69 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b001">1</xref>
###xml 305 306 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b006">6</xref>
###xml 307 308 307 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b009">9</xref>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b010">10</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b011">11</xref>
###xml 676 678 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b012">12</xref>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b015">15</xref>
###xml 710 712 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b016">16</xref>
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b017">17</xref>
###xml 745 747 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b018">18</xref>
###xml 800 802 800 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b019">19</xref>
###xml 803 805 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b025">25</xref>
###xml 824 826 824 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b022">22</xref>
###xml 827 829 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b026">26</xref>
###xml 830 832 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b032">32</xref>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b033">33</xref>
###xml 862 864 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b037">37</xref>
###xml 910 912 910 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b038">38</xref>
###xml 913 915 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b040">40</xref>
###xml 957 959 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b041">41</xref>
###xml 960 962 960 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b043">43</xref>
###xml 991 993 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b039">39</xref>
###xml 994 996 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b044">44</xref>
###xml 997 999 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b045">45</xref>
###xml 1024 1026 1024 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b046">46</xref>
###xml 1027 1029 1027 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b047">47</xref>
###xml 1051 1052 1051 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b009">9</xref>
###xml 1053 1055 1053 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b048">48</xref>
###xml 1056 1058 1056 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b053">53</xref>
###xml 1104 1106 1104 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b054">54</xref>
###xml 1107 1109 1107 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b055">55</xref>
###xml 1260 1262 1260 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b056">56</xref>
###xml 1263 1265 1263 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b062">62</xref>
###xml 1572 1580 <span type="species:ncbi:9606">patients</span>
###xml 1704 1711 <span type="species:ncbi:9606">patient</span>
Fifteen years after the discovery that SOD1 mutations can cause ALS [1], the mechanisms of toxicity are still not well understood. The dominant inheritance of most SOD1 mutations and the literature as a whole indicate that SOD1 mutations result in a toxic gain of function rather than a loss of function [6-9]. Numerous hypotheses have been proposed, reviewed in [10,11], and can be broken down conceptually into the (nonexclusive) toxic mechanisms that converge to SOD1 protein structure-function and those that converge elsewhere (downstream effects). Popular hypotheses for SOD1 variant structure and function changes include decreased stability of apo or metallated SOD1 [12-15], increased hydrophobicity [16] and aggregation propensity [17,18], susceptibility to posttranslational modification [19-25], loss of metals [22,26-32], and aberrant chemistry [33-37]. Popular hypotheses for downstream effects [38-40] include impairment of axonal transport [41-43], impairment of proteasome [39,44,45] or chaperone activity [46,47], and mitochondrial [9,48-53] or endoplasmic reticulum-Golgi dysfunction [54,55]. Notably, the only potentially toxic property thus far shared by all fALS SOD1 variants is an increased propensity to form proteinaceous aggregates [56-62]. Due to the clinical similarities between fALS and sALS, research into SOD1 mutation-related fALS may provide insight into sporadic cases. Here we demonstrate that two properties, namely, increased aggregation propensity and instability (loss of stability), are major contributors to SOD1 toxicity in ALS patients. On the basis of these results we rationalize the determinants of aggregation, the selective vulnerability of neurons, and patient survival times.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
SOD1 Mutations Have Inherently Different Toxicities
###end title 10
###begin p 11
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b063">63</xref>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b066">66</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b067">67</xref>
###xml 894 901 894 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t001">Table 1</xref>
###xml 1244 1252 1244 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g001">Figure 1</xref>
###xml 1777 1784 1777 1784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t002">Table 2</xref>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
###xml 694 701 <span type="species:ncbi:9606">patient</span>
###xml 982 990 <span type="species:ncbi:9606">patients</span>
###xml 1153 1161 <span type="species:ncbi:9606">patients</span>
###xml 1538 1545 <span type="species:ncbi:9606">patient</span>
The goal of this study is to discover the mechanisms of toxicity of fALS SOD1 mutations. Neurologists often publish the age at onset and the time from disease onset to death (also termed survival or disease duration) for their ALS patients, thereby enabling epidemiological studies that assess the risk of a given variable [63-66], which for this study include given mutations' relative toxicity and physical characteristics (physicochemical parameters). Previous studies revealed that different SOD1 mutations have inherently different toxicities (encode different mean disease durations) [67]. We expanded upon these studies with a larger set of fALS-causing SOD1 mutations as well as larger patient cohorts. Hazard ratios (relative risk of dying at a given time) of fALS SOD1 mutations and non-SOD1-related fALS compared to that of sALS were obtained from the Cox proportional hazard model (Table 1). From this result, fALS SOD1 mutations with data from at least five individual patients (full criteria for inclusion are defined in the Materials and Methods section) were significantly related to different hazards. Kaplan-Meier survival curves from patients with fALS-causing SOD1 mutations, non-SOD1-related fALS, and sALS were generated. Figure 1 illustrates that fALS SOD1 mutations encode different prognoses, ranging from considerably better (e.g., H46R, hazard rate = 0.075 x sALS) to considerably worse (e.g., A4V, hazard rate = 5.7 x sALS) than sALS. Moreover, the Log rank, Breslow, and Tarone-Ware tests, which also compare patient survival rates (i.e., each mutation versus every other fALS-causing SOD1 mutation, non-SOD1-related fALS, and sALS) using different mathematical functions, confirm that different SOD1 mutations have inherently different prognoses (Table 2).
###end p 11
###begin p 12
SOD1 Mutations Encode Inherently Different Prognoses
###end p 12
###begin title 13
###xml 5 13 <span type="species:ncbi:9606">Patients</span>
fALS Patients' Kaplan-Meier Survival Curves Illustrating Low and High Risk SOD1 Mutations
###end title 13
###begin p 14
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
###xml 225 233 <span type="species:ncbi:9606">patients</span>
Kaplan-Meier survival curves from patients with A4V (red) and H46R (blue) SOD1 mutations and sALS (green) are as shown. Disease durations from 205 patients with A4V SOD1 mutation, 63 patients with H46R SOD1 mutation, and 269 patients with sALS were used to generate these Kaplan-Meier survival curves.
###end p 14
###begin p 15
###xml 45 53 <span type="species:ncbi:9606">Patients</span>
SOD1 Mutations Are Inherently Related to ALS Patients' Disease Duration
###end p 15
###begin title 16
SOD1 Variants' Gain of Hydrophobicity, Loss of alpha-Helix, and Gain of beta-Sheet Propensity Are fALS Risk Factors, While Loss of Net Charge Is Protective
###end title 16
###begin p 17
###xml 366 373 359 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t003">Table 3</xref>
###xml 1015 1017 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b015">15</xref>
###xml 1018 1020 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b068">68</xref>
###xml 862 869 <span type="species:ncbi:9606">patient</span>
###xml 957 964 <span type="species:ncbi:9606">patient</span>
To test the hypothesis that changes to the physicochemical properties of SOD1 variants are toxic, specifically those properties known to influence protein aggregation, physicochemical properties for each protein variant (hydrophobicity, propensity to lose alpha-helices, form beta-sheets, protein net charge, etc.) were evaluated in a Cox proportional hazard model (Table 3). The hazard ratios were significantly higher than 1.0 for mutations that either increase hydrophobicity, lose alpha-helices, or form beta-sheets. In contrast, mutations that decrease the magnitude of the protein net charge correlate with hazard ratios significantly smaller than 1.0. These results indicate that changes in the SOD1 variants' properties, specifically increases in hydrophobicity and propensity to lose alpha-helices and to form beta-sheets, correlate with decreased fALS patient survival, while decreases of the magnitude of net charge correlate with increased fALS patient survival, in contradiction with previous reports [15,68].
###end p 17
###begin p 18
SOD1 Variants' Gain of Hydrophobicity, Loss of alpha-Helix, and Gain of beta-Sheet Propensity Are ALS Risk Factors, While Loss of Net Charge Is Protective
###end p 18
###begin p 19
###xml 23 25 23 25 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b069">69</xref>
###xml 1084 1087 1076 1079 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mut</sub>
###xml 1090 1092 1081 1083 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</sub>
###xml 1129 1130 1108 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 1130 1140 1109 1115 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">coil-&#945;</sub>
###xml 1153 1154 1120 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 1154 1163 1121 1127 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;-coil</sub>
###xml 1199 1202 1158 1161 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mut</sub>
###xml 1205 1207 1163 1165 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</sub>
###xml 1287 1288 1233 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 1288 1298 1234 1240 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">coil-&#945;</sub>
###xml 1310 1311 1244 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 1311 1320 1245 1251 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;-coil</sub>
Dobson and co-workers [69] introduced an equation (termed the Chiti-Dobson equation herein) to predict the changes of aggregation rates of unfolded peptides or proteins upon point mutations by their physicochemical properties. This equation was derived empirically by modeling how three physicochemical properties, hydrophobicity, secondary structure (including loss of alpha-helix and gain of beta-sheet), and protein net charge, change upon mutations (the hazard analyses for each of these properties were reported in the previous paragraph). These physicochemical property changes then were related to changes in protein aggregation rate, yielding an equation that predicts how any mutation will change the rate of protein aggregation (the predicted change of aggregation rate is referred to as the aggregation propensity). Although this equation is empirical, it is based upon first physical/chemical principles and approximates how a given mutation will change the energy (and thus the equilibrium) between a solvated and an aggregated protein. The Chiti-Dobson equation is ln(numut/nuwt) = 0.633DeltaHydr + 0.198(DeltaDeltaGcoil-alpha + DeltaDeltaGbeta-coil) - 0.491Deltacharge, in which ln(numut/nuwt) represents change of aggregation rate upon mutation, and DeltaHydr, DeltaDeltaGcoil-alpha, DeltaDeltaGbeta-coil, and Deltacharge represent the changes of hydrophobicity, free energy change for the process from alpha-helix to random coil, free energy change for the process from random coil to beta-sheet, and protein net charge from the mutation, respectively. In their landmark study, it was demonstrated that increases in hydrophobicity, losses of alpha-helices, gains of beta-sheets, and decreases in the magnitude of protein net charge increase the rate of protein aggregation.
###end p 19
###begin title 20
Protein Aggregation Propensity Is a Risk Factor of fALS
###end title 20
###begin p 21
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b070">70</xref>
###xml 212 214 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b069">69</xref>
###xml 222 224 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b069">69</xref>
###xml 244 246 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b069">69</xref>
###xml 257 259 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b069">69</xref>
###xml 272 274 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b071">71</xref>
###xml 462 472 452 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 503 505 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b072">72</xref>
###xml 905 912 895 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t004">Table 4</xref>
###xml 1001 1009 991 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g002">Figure 2</xref>
###xml 1386 1388 1376 1378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b073">73</xref>
###xml 1389 1391 1379 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b075">75</xref>
###xml 462 472 <span type="species:ncbi:7227">Drosophila</span>
###xml 586 593 <span type="species:ncbi:9606">patient</span>
The Chiti-Dobson equation and the many equations it inspired are robust and versatile, having successfully predicted aggregation rates of diverse disease-associated proteins [70], including amyloid beta-peptide [69], tau [69], alpha-synuclein [69], amylin [69], lysozyme [71], etc. Moreover, increases in the predicted rates of aggregation of various mutations in amyloid beta-peptide were shown to relate to increased neuronal dysfunction and degeneration in a Drosophila model of Alzheimer's disease [72]. To test the hypothesis that protein aggregation propensity is related to fALS patient survival, the Chiti-Dobson equation was used to predict the aggregation propensities of fALS-causing SOD1 mutations. We started this study by validating the Chiti-Dobson equation, taking all experimental protein aggregation rate data available at the inception of our study (data reported as of 2005, listed in Table 4) and recalibrating the equation. The detailed results of the validation are reported in Figure 2. In summary, the Chiti-Dobson equation was verified for use in fALS, and the statistical correlation between the physicochemical parameters (hydrophobicity, net charge, and secondary structure) and the aggregation propensity remained and changed only marginally. Since the time we validated the Chiti-Dobson equation, a number of papers also validated their general approach [73-75]. Even so, we have included our own analysis since it provides exposure to the physical basis of aggregation propensity. Furthermore, inclusion of this data makes this study self-contained so that all of the data necessary to support or disprove our model are contained herein. Notably, this paper's conclusions were the same using both the original and the recalibrated Chiti-Dobson equation.
###end p 21
###begin p 22
Data Used To Rederive the Chiti-Dobson Equation
###end p 22
###begin title 23
Rederivation and Validation of the Chiti-Dobson Equation
###end title 23
###begin p 24
###xml 494 501 494 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t004">Table 4</xref>
###xml 536 539 535 538 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mut</sub>
###xml 542 544 540 542 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</sub>
The original Chiti-Dobson equation was rederived by correlating all known empirically measured mutation-related changes in protein aggregation rates as of 2005 with the corresponding changes in the physicochemical properties of charge, hydrophobicity, and secondary structure. Importantly, aggregation rate data were not taken directly from the publication that presented the Chiti-Dobson equation; instead these values were calculated from their respective original publication if applicable (Table 4). The dependence of observed ln(numut/nuwt) on hydrophobicity, secondary structure, and charge changes were still observed after the addition of extra protein aggregation data.
###end p 24
###begin p 25
###xml 43 46 42 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mut</sub>
###xml 49 51 47 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</sub>
###xml 252 253 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 253 263 235 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">coil-&#945;</sub>
###xml 276 277 246 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 277 286 247 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;-coil</sub>
(A) The relationship between observed ln(numut/nuwt) and Deltahydrophobicity. To insure that the effect of hydrophobicity change was considered independent of other physiochemical properties, only mutations that had a Deltacharge of 0 and a |DeltaDeltaGcoil-alpha + DeltaDeltaGbeta-coil| of less than 2.5 kJ/mol were considered.
###end p 25
###begin p 26
###xml 43 46 42 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mut</sub>
###xml 49 51 47 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</sub>
###xml 67 68 57 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 68 78 58 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">coil-&#945;</sub>
###xml 91 92 69 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 92 101 70 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;-coil</sub>
(B) The relationship between observed ln(numut/nuwt) and DeltaDeltaGcoil-alpha + DeltaDeltaGbeta-coil. To insure that the effect of secondary structure change was considered independent of other physiochemical properties, only mutations which had a Deltacharge of 0 and a |Deltahydrophobicity| of less than 3 kcal/mol were considered.
###end p 26
###begin p 27
###xml 47 50 46 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mut</sub>
###xml 53 55 51 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</sub>
###xml 269 270 251 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 270 280 252 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">coil-&#945;</sub>
###xml 293 294 263 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 294 303 264 270 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;-coil</sub>
###xml 658 666 625 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g004">Figure 4</xref>
###xml 772 773 739 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 828 836 795 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g004">Figure 4</xref>
###xml 668 675 <span type="species:ncbi:9606">Patient</span>
(C) The relationship between the observed ln(numut/nuwt) and Deltacharge. To ensure that the effect of charge change was considered independent of other physiochemical properties, only mutations that had a |Deltahydrophobicity| of less than 3 kcal/mol and a |DeltaDeltaGcoil-alpha + DeltaDeltaGbeta-coil| of less than 2.5 kJ/mol were considered. Wild-type protein was used as a data point at (0,0) in all of the three graphs. The rederived slopes from this figure for the three factors, 0.95 for hydrophobicity, 0.18 for secondary structure, and -0.78 for charge, were applied to calculate aggregation propensities of fALS-causing SOD1 variants presented in Figure 4. Patient survival times were plotted against these aggregation propensities; the corresponding slope and R values differ less than 5% compared to the results in Figure 4 (unpublished data), validating the Chiti-Dobson equation.
###end p 27
###begin title 28
###xml 133 141 <span type="species:ncbi:9606">Patients</span>
###xml 174 182 <span type="species:ncbi:9606">Patients</span>
Synergistic Increases in SOD1 Aggregation Propensity and Increases of Instability Are Associated with Decreases in Survival for fALS Patients (Data Weighted by the Number of Patients)
###end title 28
###begin p 29
###xml 80 87 <span type="species:ncbi:9606">patient</span>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
(A) An increase in aggregation propensity is associated with a decrease in fALS patient survival. Single point mutations of SOD1 found in fALS patients with corresponding reported stability values in (B) were considered. Aggregation propensities for each fALS mutation were calculated using the Chiti-Dobson equation, normalized such that 0 represents the least and 1 represents the most aggregation prone proteins, and the corresponding disease duration (survival) was plotted versus this value.
###end p 29
###begin p 30
(B) An increase in SOD1 instability is associated with severe disease. All instability values of apo SOD1 reported in the literature were normalized such that 0 represents the most and 1 represents the least stable proteins, and corresponding disease durations were plotted versus these values.
###end p 30
###begin p 31
###xml 93 100 <span type="species:ncbi:9606">patient</span>
###xml 232 239 <span type="species:ncbi:9606">patient</span>
###xml 344 352 <span type="species:ncbi:9606">patients</span>
###xml 468 476 <span type="species:ncbi:9606">patients</span>
(C) Increase in SOD1 aggregation propensity and gain of instability synergistically decrease patient survival. Normalized aggregation propensity in (A) and instability in (B) were summed and normalized to the range from 0 to 1, and patient survival was plotted versus this value. The data used in these three graphs (disease durations from 580 patients with 28 different fALS-causing SOD1 mutations with reported stability values) were weighted based on the number of patients for each mutation using SPSS version 15.0.
###end p 31
###begin p 32
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Note that the correlation between the size of each data point and the number of patients for (A-C) is shown as an inset in (C).
###end p 32
###begin title 33
###xml 138 146 <span type="species:ncbi:9606">Patients</span>
Synergistic Increases in SOD1 Aggregation Propensity and Losses of Thermodynamic Stability Are Associated with Decreased Survival of fALS Patients (Using Unweighted Data)
###end title 33
###begin p 34
###xml 76 83 <span type="species:ncbi:9606">patient</span>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
(A) An increase in aggregation propensity is associated with decreased fALS patient survival. Single point mutations found in fALS patients with corresponding reported thermodynamic stabilities in (B) were considered.
###end p 34
###begin p 35
(B) A loss of SOD1 thermodynamic stability is associated with severe disease.
###end p 35
###begin p 36
###xml 93 100 <span type="species:ncbi:9606">patient</span>
###xml 175 183 <span type="species:ncbi:9606">patients</span>
###xml 311 319 <span type="species:ncbi:9606">patients</span>
(C) Increase in SOD1 aggregation propensity and gain of instability synergistically decrease patient survival. The data used in these three graphs (disease durations from 580 patients with 28 different fALS-causing SOD1 mutations with reported stability values) were treated equally regardless of the number of patients using the software SigmaPlot 9.0 (Systat Software, Inc.). SPSS 15.0 also was used on this analysis, and identical results were obtained.
###end p 36
###begin p 37
###xml 266 267 266 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 363 364 363 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 458 466 458 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g003">Figure 3</xref>
###xml 673 681 673 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g004">Figure 4</xref>
###xml 694 695 694 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 700 701 700 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 906 908 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b076">76</xref>
###xml 909 911 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b079">79</xref>
###xml 931 933 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b080">80</xref>
###xml 1201 1208 1201 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t003">Table 3</xref>
###xml 1644 1646 1644 1646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b081">81</xref>
###xml 1736 1752 1736 1752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">after nucleation</italic>
###xml 1778 1789 1778 1789 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">after onset</italic>
###xml 12 19 <span type="species:ncbi:9606">patient</span>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
###xml 663 671 <span type="species:ncbi:9606">patients</span>
###xml 1110 1118 <span type="species:ncbi:9606">patients</span>
The average patient survival times for different SOD1 variants with measured thermodynamic stabilities were plotted against corresponding predicted aggregation propensities, and linear regression analysis weighted by the number of patients for each mutation yielded R (multiple correlation coefficient, with a larger value indicating a stronger relationship) and P (value less than 0.05 implies a significant result) values of 0.58 and <0.001, respectively (Figure 3A). The severity of fALS thus is related to mutation-induced increases in SOD1 aggregation propensity. The same plot was performed with the linear regression analysis not weighted by the number of patients (Figure 4A), yielding R and P values of 0.23 and 0.2, respectively. Unfortunately, the published epidemiology data do not provide the information necessary to stratify for known ALS covariates, including lifestyle (diet and smoking) [76-79], palliative care [80], bulbar onset, etc., and weighted data are more likely to account for differences in these factors. The Chiti-Dobson equation results for all fALS-causing SOD1 mutations with patients' survival data also were evaluated in a univariate Cox proportional hazard model (Table 3). The hazard ratio for the Chiti-Dobson equation result was significantly higher than 1.0, which also indicates that aggregation propensity is a risk factor for fALS. Previous studies of Huntington's disease revealed an inverse relationship between the length of glutamine repeat of huntingtin and age of disease onset. The authors of this previous study concluded that disease onset correlates with rate of nucleation of aggregation [81]. We demonstrate here an inverse relationship between the rate of aggregation elongation after nucleation and the disease duration after onset.
###end p 37
###begin title 38
Protein Instability Is a Risk Factor for fALS
###end title 38
###begin p 39
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b082">82</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b085">85</xref>
###xml 466 467 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 563 564 551 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 564 565 552 553 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 1164 1166 1152 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b032">32</xref>
###xml 1352 1353 1336 1337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 1353 1354 1337 1338 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 1411 1412 1387 1388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 1832 1834 1808 1810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b015">15</xref>
###xml 1835 1837 1811 1813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b031">31</xref>
###xml 1838 1840 1814 1816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b060">60</xref>
###xml 1841 1843 1817 1819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b086">86</xref>
###xml 1844 1846 1820 1822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b088">88</xref>
###xml 1904 1905 1872 1873 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 1915 1916 1879 1880 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 1916 1917 1880 1881 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 2175 2176 2131 2132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 2186 2187 2138 2139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 2187 2188 2139 2140 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 2261 2262 2205 2206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 2286 2287 2226 2227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 2287 2288 2227 2228 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 2392 2393 2332 2333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 2402 2403 2342 2343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2413 2421 2353 2361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g005">Figure 5</xref>
On the basis of our observation that predicted increased protein aggregation correlates with increased disease severity and previous data indicating that protein unfolding or misfolding promote aggregation [82-85], we tested the hypothesis that a loss of protein stability also could be a risk factor for ALS. For the sake of simplicity, we use the term instability throughout this article, with instability defined as the inverse of either the normalized DeltaDeltaG (unfolding free energy change difference between mutant and wild-type SOD1) or normalized DeltaTm (melting point difference between mutant and wild-type SOD1). Instability was considered for two reasons: (1) the Chiti-Dobson equation predicts the aggregation rates of unfolded proteins (it was derived from the aggregation rates of proteins in high trifluoroethanol concentrations that contained secondary but no tertiary structure), and therefore, formally, unfolding must occur prior to aggregation, and (2) unfolding is known to speed protein aggregation in vitro to the extent that without chemically induced unfolding induction periods extend from months to years, as demonstrated for SOD1 [32]. Aggregation in vivo therefore may require protein unfolding. Before using stability data published by different laboratories using different methods (melting point, which yields DeltaTm, or chaotroph-induced unfolding, which yields DeltaDeltaG), we sought to determine the reliability of the data. If different laboratories reported similar values of stability for the same mutants, then the data could be deemed reliable. Therefore, all published measurements of apo SOD1 stability (metallated SOD1 calorimetry data often bear the characteristics of irreversible denaturation, probably via Cu-catalyzed disulfide bond formation, and is therefore less reliable) [15,31,60,86-88] were compiled, and the experimental values of DeltaDeltaG and DeltaTm were normalized to the range from 0 to 1 (described in the Materials and Methods section), with 0 representing the least stable, and 1 representing the most stable (highest stability) variant. Through the use of all of the data from mutants where DeltaDeltaG and DeltaTm were measured by different laboratories, a plot of normalized DeltaDeltaG versus normalized DeltaTm was created. Good interlaboratory correlation of measured stability values was observed (slope = 0.94, R = 0.90, P = 0.002; Figure 5), and we therefore deemed the stability data reliable for use.
###end p 39
###begin title 40
###xml 72 73 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 73 74 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 89 90 77 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
Correlation between Measures of Stability, Specifically Normalized DeltaTm and DeltaDeltaG, Reported from Different Groups for Apo SOD1 Variants
###end title 40
###begin p 41
###xml 37 38 33 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 38 39 34 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 54 55 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 117 118 101 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 118 119 102 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 220 221 192 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 221 222 193 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 237 238 201 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 344 345 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 345 346 305 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 361 362 313 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
The variants with both measured DeltaTm and DeltaDeltaG were plotted, and a good correlation between normalized DeltaTm and normalized DeltaDeltaG was observed. This correlation provides the rationale for averaging DeltaTm and DeltaDeltaG and taking the average value as an indicator for stability of fALS-related variants. The normalized DeltaTm and DeltaDeltaG were obtained as described in the Materials and Methods section.
###end p 41
###begin p 42
###xml 206 207 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 212 213 212 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 255 263 255 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g003">Figure 3</xref>
###xml 371 379 371 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g004">Figure 4</xref>
###xml 392 393 392 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 405 406 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 661 663 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b089">89</xref>
###xml 6 13 <span type="species:ncbi:9606">patient</span>
###xml 171 179 <span type="species:ncbi:9606">patients</span>
###xml 361 369 <span type="species:ncbi:9606">patients</span>
###xml 515 522 <span type="species:ncbi:9606">patient</span>
Next, patient survival data for fALS-causing SOD1 variants were plotted against corresponding instability values, and linear regression analysis weighted by the number of patients for each mutation yielded R and P values of 0.71 and <0.001, respectively (Figure 3B). The same plot was performed with the linear regression analysis not weighted by the number of patients (Figure 4B), yielding R = 0.34 and P = 0.07. A gain of SOD1 instability (loss of stability) upon mutation therefore is related to decreased fALS patient survival. Increased in vitro instability is consistent with previous findings that the in vivo half-lives of SOD1 variants are decreased [89].
###end p 42
###begin title 43
Protein Aggregation Propensity and Protein Instability Are Synergistic Risk Factors for fALS
###end title 43
###begin p 44
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b090">90</xref>
###xml 540 548 540 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g003">Figure 3</xref>
###xml 550 559 550 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-0060170-sg001">Figure S1</xref>
###xml 1055 1056 1055 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 1061 1062 1061 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1104 1112 1104 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g003">Figure 3</xref>
###xml 1220 1228 1220 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g004">Figure 4</xref>
###xml 1241 1242 1241 1242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 1254 1255 1254 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1561 1562 1561 1562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 1562 1563 1562 1563 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1869 1876 1869 1876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t005">Table 5</xref>
###xml 2066 2073 2066 2073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t005">Table 5</xref>
###xml 2311 2318 2311 2318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t005">Table 5</xref>
###xml 2367 2376 2367 2376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g003">Figures 3</xref>
###xml 2381 2382 2381 2382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g004">4</xref>
###xml 2412 2419 2412 2419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t003">Table 3</xref>
###xml 2543 2550 2543 2550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t005">Table 5</xref>
###xml 2572 2579 2572 2579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t003">Table 3</xref>
###xml 2641 2648 2641 2648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t005">Table 5</xref>
###xml 222 229 <span type="species:ncbi:9606">patient</span>
###xml 389 397 <span type="species:ncbi:9606">patients</span>
###xml 860 867 <span type="species:ncbi:9606">Patient</span>
###xml 1020 1028 <span type="species:ncbi:9606">patients</span>
###xml 1210 1218 <span type="species:ncbi:9606">patients</span>
###xml 1310 1317 <span type="species:ncbi:9606">patient</span>
###xml 1663 1671 <span type="species:ncbi:9606">patients</span>
###xml 2702 2709 <span type="species:ncbi:9606">patient</span>
Previous results from computer simulations indicate a multistep process for aggregation via destabilization [90], encouraging us to understand the combined effect of aggregation propensity and protein instability upon ALS patient survival. On the basis of their respective multiple correlation coefficients and slopes, aggregation propensity and instability are equal contributors to fALS patients' survival. Moreover, no obvious correlation between protein instability and aggregation propensity was observed for the SOD1 variants used in Figure 3 (Figure S1), indicating that increased instability is not responsible for the increased predicted protein aggregation propensity. The combination of instability and aggregation propensity represents the relative energy in proceeding from folded to unfolded apo SOD1 and then from unfolded to aggregated states. Patient survival was plotted against corresponding summed instability and aggregation propensity values. A linear regression analysis weighted by the number of patients for each mutation yielded R and P values of 0.83 and <0.001, respectively (Figure 3C). The same plot was performed with the linear regression analysis not weighted by the number of patients (Figure 4C), yielding R = 0.47 and P = 0.01. The improved statistical result of predicting patient survival after combining instability and aggregation propensity indicates that aggregation occurs from unfolded or partially unfolded SOD1. The stability data used herein were for apo SOD1, and therefore the absence of metals is implicit. The R2 value was 0.69 from the weighted data, indicating that 69% of the intrinsic variability these fALS patients' survival resulted from the combination of increased aggregation propensity and instability. Additionally, aggregation propensity and instability were evaluated in a Cox proportional hazard model (Table 5). The hazard ratios were significantly higher than 1.0 for both factors. The sum of aggregation propensity and instability also was evaluated in a univariate Cox proportional hazard model (Table 5). The hazard ratio for this sum was also significantly higher than 1.0, further indicating that aggregation propensity and instability are synergistic risk factors for fALS. Note that the aggregation propensity and instability tested in Table 5 were normalized to the range from 0 to 1 (as in Figures 3 and 4), while the values tested in Table 3 were not normalized. As a result of normalization, which decreased the value range of tested factors, the hazard ratios of Table 5 are much larger than Table 3, and therefore the large values of hazard ratios reported in Table 5 should not be overinterpreted. Significantly, a fALS patient with an SOD1 mutation of relatively low aggregation propensity and high stability is expected to survive longer after disease onset. It has not escaped our attention that the rate of protein aggregation has implications in both sporadic diseases and aging; for example, the toxicity of a given posttranslational modification is a function of its effect on protein stability and aggregation propensity.
###end p 44
###begin p 45
SOD1 Variants' Aggregation Propensity and Instability Are ALS Risk Factors
###end p 45
###begin title 46
Discussion
###end title 46
###begin p 47
###xml 899 901 899 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b032">32</xref>
###xml 963 965 963 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b028">28</xref>
###xml 966 968 966 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b091">91</xref>
###xml 969 971 969 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b096">96</xref>
###xml 1123 1125 1123 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b015">15</xref>
###xml 1165 1167 1165 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b086">86</xref>
###xml 1204 1211 <span type="species:ncbi:9606">patient</span>
###xml 1277 1284 <span type="species:ncbi:9606">patient</span>
We describe here synergistic gains of toxic functions of SOD1 in ALS. These are the first results in any neurodegenerative disease demonstrating that protein instability and aggregation propensity are synergistic risk factors. The fact that there are two synergistic risk factors rather than a single toxic gain of function probably has delayed the discovery of the mechanisms of fALS mutant SOD1 toxicity. The SOD1 stability data used in this paper were measured from apo SOD1, and the aggregation rate data used to create the Chiti-Dobson model were from in vitro unfolded proteins. Therefore, formally, the combination of instability and aggregation propensity represents the relative energy in proceeding from apo folded to unfolded SOD1 and then from unfolded to aggregated states. It has been demonstrated experimentally that apo SOD1 has a faster rate of aggregation than that of holo forms [32]. Partial unfolding/misfolding also can lead to aggregation [28,91-96], and our results cannot rule out a role for the aggregation of partially folded, including metallated, SOD1. Previous studies revealed a correlation [15] and conversely a lack of correlation [86] between SOD1 variant stability and patient disease duration. Correlation between SOD1 variant stability and patient disease duration, however, required that the authors omit stability data of 4 of the 15 variants from their regression analysis (on the basis that these variants change the net charge of SOD1).
###end p 47
###begin p 48
###xml 16 23 16 23 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t003">Table 3</xref>
###xml 263 265 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b069">69</xref>
###xml 266 268 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b073">73</xref>
###xml 269 271 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b097">97</xref>
###xml 543 550 536 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t005">Table 5</xref>
###xml 706 713 699 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t003">Table 3</xref>
###xml 834 841 827 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t003">Table 3</xref>
###xml 908 910 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b015">15</xref>
###xml 911 913 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b068">68</xref>
###xml 85 92 <span type="species:ncbi:9606">patient</span>
###xml 1073 1080 <span type="species:ncbi:9606">patient</span>
###xml 1175 1183 <span type="species:ncbi:9606">patients</span>
As presented in Table 3, SOD1 variants' loss of net charge correlates with increased patient survival, while gain of hydrophobicity, loss of alpha-helix, and gain of beta-sheet propensity are ALS risk factors. On the basis of Dobson and co-workers' related work [69,73,97], a loss of net charge is predicted to increase the aggregation propensity of unfolded proteins. If aggregation is toxic, then one would expect loss of net charge to be toxic. In contrast to the synergistic effects for aggregation propensity and instability presented in Table 5, the correlation of loss of net charge with increased survival has an effect of decreasing the hazard ratio presented in the univariate model presented in Table 3. We demonstrate that mutations causing the entire protein to approach neutrality are protective in the context of fALS (Table 3) rather than deleterious as proposed by Oliveberg and co-workers [15,68]. These results should be cautiously interpreted since in contrast to our Cox proportional hazard model result that loss of net charge is protective, the mean patient survival for loss of net charge and gain of net charge mutations, unweighted by the number of patients, are 7.1 and 6.9 years, respectively. Further study clearly is required to understand the role of charge in ALS etiology.
###end p 48
###begin p 49
###xml 80 87 80 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t001">Table 1</xref>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b098">98</xref>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b067">67</xref>
###xml 360 369 360 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g003">Figures 3</xref>
###xml 374 375 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g004">4</xref>
###xml 473 482 473 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-0060170-sg002">Figure S2</xref>
###xml 1008 1010 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b099">99</xref>
###xml 1011 1014 1011 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b100">100</xref>
###xml 1131 1134 1131 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b101">101</xref>
###xml 221 229 <span type="species:ncbi:9606">patients</span>
In contrast with the strong familiality shown for disease duration after onset (Table 1), SOD1-mediated ALS showed modest familiality with respect to onset, accounting for only 42% of the variability in A4V and D90A fALS patients [98], and with only G37R and L38V mutations of SOD1 being significant covariates of age of onset [67]. The same analysis shown in Figures 3 and 4 was performed using age at disease onset rather than disease duration as the dependant variable (Figure S2), and little or no relationship between disease onset and aggregation propensity or instability was observed. The Chiti-Dobson equation predicts the rate of aggregation after nucleation (rate of elongation). It is tempting therefore to speculate that the rate of nucleation is a determinant of age at onset. Testing this hypothesis would require the development of a model that can predict nucleation rates based upon physicochemical parameters, a task that is hampered by the stochastic nature of in vitro nucleation times [99,100] but that should now be possible given our recent development of methods for modeling in vitro nucleation kinetics [101].
###end p 49
###begin p 50
###xml 362 365 362 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b102">102</xref>
###xml 366 369 366 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b103">103</xref>
###xml 63 70 <span type="species:ncbi:9606">patient</span>
###xml 267 273 <span type="species:ncbi:9606">people</span>
Although our model accounts for 69% of the variability in fALS patient survival after onset, there are clearly genetic components of fALS that our model cannot account for. For example, while D90A is normally a dominantly inherited mutation in North America, 2.5% of people in Sweden and Finland are heterozygous asymptomatic carriers of the D90A SOD1 mutation [102,103] and require two mutant alleles before presenting ALS symptoms. Notably, our results and conclusions were unaffected by including or excluding D90A survival times during data analysis.
###end p 50
###begin p 51
###xml 250 253 250 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b101">101</xref>
###xml 254 257 254 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b104">104</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b039">39</xref>
###xml 508 511 508 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b105">105</xref>
###xml 76 83 <span type="species:ncbi:9606">patient</span>
It is postulated that diseases for which protein aggregation contributes to patient death will (1) develop in cells with the highest concentration of the aggregation-prone protein in accordance with the concentration dependence of aggregation rates [101,104] and (2) have a prognosis influenced by the aggregation propensity of the aggregating protein, in accordance with the results reported herein. Motor neurons are the cells in the ventral horn of the spinal cord with the highest SOD1 concentration [39,105], perhaps explaining an aspect of the selective vulnerability of these cells.
###end p 51
###begin p 52
###xml 147 150 147 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b106">106</xref>
###xml 151 154 151 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b107">107</xref>
###xml 220 223 220 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b108">108</xref>
###xml 224 227 224 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b109">109</xref>
###xml 246 249 246 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b110">110</xref>
###xml 270 273 270 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b111">111</xref>
###xml 369 372 369 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b108">108</xref>
###xml 373 376 373 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b112">112</xref>
###xml 501 504 501 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b106">106</xref>
###xml 684 687 684 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b113">113</xref>
###xml 688 691 688 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b114">114</xref>
###xml 724 727 724 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b114">114</xref>
###xml 728 731 728 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b115">115</xref>
###xml 788 789 788 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b007">7</xref>
###xml 790 791 790 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b009">9</xref>
###xml 792 794 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b023">23</xref>
###xml 795 797 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b059">59</xref>
###xml 798 801 798 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b116">116</xref>
###xml 802 805 802 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b128">128</xref>
###xml 853 855 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b056">56</xref>
###xml 856 858 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b058">58</xref>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b059">59</xref>
###xml 862 865 862 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b116">116</xref>
###xml 866 869 866 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b118">118</xref>
###xml 870 873 870 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b119">119</xref>
###xml 874 877 874 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b129">129</xref>
###xml 878 881 878 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b131">131</xref>
###xml 615 623 <span type="species:ncbi:9606">patients</span>
###xml 714 722 <span type="species:ncbi:9606">patients</span>
Protein aggregation is a hallmark of many neurodegenerative diseases, including ALS. The toxicity of aggregation is fiercely debated (reviewed in [106,107]), fueled by reproducible evidence that aggregates can be toxic [108,109], have no effect [110], or be protective [111]. We propose that aggregates on either extreme of size, i.e., small protofibrillar aggregates [108,112] or aggregates large enough to clog axons, are more toxic, while midsize microscopically visible aggregates are less toxic [106]. Our data indicate that the increased aggregation propensity of SOD1 is related to decreased survival of ALS patients. Notably aggregation of SOD1 has been demonstrated in fALS [113,114] and a subset of sALS patients [114,115], 18 fALS rodent models of 13 different SOD1 mutations [7-9,23,59,116-128], and at least 13 SOD1 mutants in cell models [56,58,59,116,118,119,129-131].
###end p 52
###begin title 53
Materials and Methods
###end title 53
###begin title 54
###xml 13 21 <span type="species:ncbi:9606">patients</span>
Familial ALS patients' disease duration and age of onset.
###end title 54
###begin p 55
###xml 357 364 357 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t006">Table 6</xref>
###xml 1808 1816 1808 1816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g003">Figure 3</xref>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
###xml 151 158 <span type="species:ncbi:9606">patient</span>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
###xml 374 382 <span type="species:ncbi:9606">patients</span>
###xml 633 641 <span type="species:ncbi:9606">patients</span>
###xml 1039 1046 <span type="species:ncbi:9606">patient</span>
###xml 1265 1273 <span type="species:ncbi:9606">patients</span>
###xml 1401 1409 <span type="species:ncbi:9606">patients</span>
###xml 1909 1917 <span type="species:ncbi:9606">patients</span>
Familial ALS patients' data were taken from all of the available literature. Disease duration was initiated with onset of the first symptoms until the patient's death or when respiratory assistance was required for patients' survival. The average duration and onset for each mutation were calculated as the weighted average based on the number of patients (Table 6). If the patients were still reported to be alive without respiratory assistance at the end of a study, then their disease durations were not used to calculate the average unless the known duration value was larger than the average calculated with only durations from patients deceased or with respiratory assistance. For studies reporting average disease duration and Kaplan-Meier curves, the reported average durations were used to calculate the weighted averages. The current unavailability of  made it impossible to review the references provided by the website (from which we had taken survival times before it became unavailable), which created the risk of counting a patient's disease onset or survival twice, and made reproducing our study impossible for other groups. We therefore opted not to report data from this website in this study, thereby eliminating no more than 67 (there were 67  patients' data without accompanying literature references that may, or may not, have been represented by our literature search) of 1319 patients' data. However, we did perform a complete, alternative set of analyses that did include  data (unpublished data), and the statistical correlations in the figures and tables shown herein persisted. Mean values of disease durations also were obtained from Kaplan-Meier curves and tested on SOD1 mutations with known experimental thermodynamic stabilities, and the results were comparable to those in Figure 3. Since the weighted average method can provide disease duration regardless of the number of patients, we opted for its use.
###end p 55
###begin p 56
###xml 100 108 <span type="species:ncbi:9606">Patients</span>
Disease Durations and Age of Onsets for SOD1 Mutation Related fALS, Non-SOD1-Related fALS, and sALS Patients
###end p 56
###begin title 57
Kaplan-Meier survival curves, the log rank tests, and the Cox proportional hazard model.
###end title 57
###begin p 58
###xml 1116 1119 1116 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b132">132</xref>
###xml 368 376 <span type="species:ncbi:9606">patients</span>
###xml 547 555 <span type="species:ncbi:9606">patients</span>
###xml 636 643 <span type="species:ncbi:9606">patient</span>
###xml 888 896 <span type="species:ncbi:9606">patients</span>
###xml 960 968 <span type="species:ncbi:9606">patients</span>
###xml 1049 1057 <span type="species:ncbi:9606">patients</span>
###xml 1210 1218 <span type="species:ncbi:9606">patients</span>
###xml 1238 1246 <span type="species:ncbi:9606">patients</span>
###xml 1305 1313 <span type="species:ncbi:9606">patients</span>
###xml 1329 1336 <span type="species:ncbi:9606">patient</span>
###xml 1603 1611 <span type="species:ncbi:9606">patients</span>
###xml 1666 1673 <span type="species:ncbi:9606">patient</span>
Kaplan-Meier curves of survival for different fALS-causing SOD1 mutations, non-SOD1-related fALS, and sALS were generated. The hazard ratios of different fALS-causing SOD1 mutations and non-SOD1-related fALS compared to sALS were tested as a category variable by Cox proportional hazard model analysis. For studies reporting Kaplan-Meier curves but without individual patients' data, the Engauge Digitizer 4.1 software was used to obtain coordinates for cumulative survival at each time point. This information was used to calculate the number of patients not surviving at each time point under the assumption that there is no censored patient (with unknown exact survival time because of being alive at the end of study, lost to follow-up, or withdrawal from the study) within the course of survival curves. For cumulative survival not reaching 0 at the end of study, those fractions of patients were treated as censored. The error of the estimated number of patients is less than 5% of the number reported. To eliminate the chance that one or two patients' survival data bias the analysis result, a rule of thumb [132] requiring that each tested fALS-related SOD1 mutation includes at least five noncensored patients was applied. Since patients' survival was reported only as an average from a group of patients and individual patient's survival information was not described in some publications, one or two publications' survival data might bias the analysis result. To eliminate this chance of bias, the rule of thumb was modified as requiring at least five independent descriptions of noncensored patients' survival data (a reported average without individual patient's survival information was treated as one description). The statistical analysis was performed with the software SPSS 15.0 (SPSS, Inc.).
###end p 58
###begin title 59
Aggregation propensity calculated from the Chiti-Dobson equation.
###end title 59
###begin p 60
###xml 142 144 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b069">69</xref>
###xml 260 261 253 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 261 266 254 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 266 268 255 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</sup>
###xml 273 274 262 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 274 279 263 264 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 279 282 264 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mut</sup>
###xml 304 305 281 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 305 315 282 288 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">coil-&#945;</sub>
###xml 627 628 600 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 628 633 601 602 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 655 656 624 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 656 661 625 626 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 703 704 668 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 704 709 669 670 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 709 711 670 672 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</sup>
###xml 716 717 677 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 717 722 678 679 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 722 725 679 682 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mut</sup>
###xml 776 777 733 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 777 782 734 735 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 782 784 735 737 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</sup>
###xml 785 786 738 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 786 791 739 740 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sub>
###xml 791 794 740 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mut</sup>
###xml 909 910 842 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 910 920 843 849 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">coil-&#945;</sub>
###xml 936 937 857 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 937 946 858 864 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;-coil</sub>
###xml 1012 1019 930 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t001">Table 1</xref>
###xml 1024 1026 942 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b069">69</xref>
###xml 1038 1041 955 958 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mut</sub>
###xml 1044 1046 960 962 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</sub>
###xml 1097 1099 1013 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b069">69</xref>
###xml 1233 1235 1149 1151 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ap</sub>
###xml 1241 1243 1157 1159 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ap</sub>
###xml 1249 1251 1165 1167 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ap</sub>
###xml 1262 1264 1178 1180 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ap</sub>
###xml 1272 1274 1188 1190 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ap</sub>
###xml 332 337 <span type="species:ncbi:9606">human</span>
###xml 430 435 <span type="species:ncbi:9606">human</span>
The hydrophobicity, beta-sheet propensity, and charge values for the amino acid residues were obtained from the Supplementary Information of [69]. While applying the AGADIR algorithm at  to obtain alpha-helical propensities for wild-type (wt) and mutant (mut) Palphawt and Palphamut values for DeltaDeltaGcoil-alpha calculation for human SOD1, the parameters of pH 7, 310 K, and ionic strength of 0.100 were used. For the protein human SOD1, the N terminus is acetylated, and the C terminus is free in vivo. After the prediction at the residue level was output, the value in the column "Hel" at a specific residue was taken as Palpha. If a value of 0 for Palpha was obtained, then 0.1 was added to both Palphawt and Palphamut values for the correct mathematical meaning of ln(Palphawt/Palphamut) (F. Chiti, personal communication). The Chiti-Dobson equation terms, Deltahydrophobicity, Deltacharge, DeltaDeltaGcoil-alpha, and DeltaDeltaGbeta-coil, were calculated based on equations illustrated in the legend of Table 1 of [69]. The ln(numut/nuwt) values were calculated based on Equation 1 from [69] and normalized from 0 to 1 using the equation normalized aggregation propensity = (aggregation propensity before normalization - MINap)/(MAXap - MINap), with MINap and MAXap as the minimum and maximum aggregation propensities of fALS-causing mutations with known thermodynamic stabilities, respectively, so that the larger normalized values correlate to larger aggregation propensities.
###end p 60
###begin title 61
###xml 21 22 13 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
Normalized DeltaDeltaG.
###end title 61
###begin p 62
###xml 45 46 37 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 89 90 77 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 90 91 78 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 237 238 217 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 262 269 242 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t002">Table 2</xref>
###xml 274 276 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b015">15</xref>
###xml 337 338 309 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 408 409 372 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 423 424 379 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 468 469 416 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 458 469 414 417 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;&#916;<italic>G</italic></sub>
###xml 485 486 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 475 486 423 426 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;&#916;<italic>G</italic></sub>
###xml 502 503 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 492 503 432 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;&#916;<italic>G</italic></sub>
###xml 524 525 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 514 525 446 449 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;&#916;<italic>G</italic></sub>
###xml 543 544 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 533 544 457 460 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;&#916;<italic>G</italic></sub>
###xml 592 593 500 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
The free energy change difference (DeltaDeltaG) and melting temperature difference (DeltaTm) of unfolding a pathogenic variant and wild-type protein are parameters used to characterize the thermodynamic stability of a protein. DeltaDeltaG values were taken from Table 2 of [15]. To graph with other protein stability data, the DeltaDeltaG values were normalized by applying the equation normalized DeltaDeltaG = (DeltaDeltaG values before normalization - MINDeltaDeltaG)/(MAXDeltaDeltaG - MINDeltaDeltaG), with MINDeltaDeltaG and MAXDeltaDeltaG as the minimum and maximum values of DeltaDeltaG in this dataset, respectively.
###end p 62
###begin title 63
###xml 16 17 12 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 17 18 13 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
Normalized DeltaTm.
###end title 63
###begin p 64
###xml 5 6 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 6 7 2 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 31 38 27 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t001">Table 1</xref>
###xml 43 45 39 41 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b086">86</xref>
###xml 48 55 44 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t001">Table 1</xref>
###xml 60 62 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b060">60</xref>
###xml 65 72 61 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t002">Table 2</xref>
###xml 77 79 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b087">87</xref>
###xml 82 89 78 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060170-t003">Table 3</xref>
###xml 94 96 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b088">88</xref>
###xml 116 118 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b031">31</xref>
###xml 126 127 118 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 127 128 119 120 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 142 144 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b060">60</xref>
###xml 145 147 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b087">87</xref>
###xml 148 150 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b088">88</xref>
###xml 232 233 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 233 234 221 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 248 250 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b031">31</xref>
###xml 251 253 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060170-b086">86</xref>
###xml 277 278 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 278 279 262 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 328 329 308 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 329 330 309 310 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 393 394 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 394 395 370 371 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 412 413 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 413 414 385 386 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 453 454 421 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 448 455 420 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;<italic>T</italic>m</sub>
###xml 466 467 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 461 468 429 432 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;<italic>T</italic>m</sub>
###xml 479 480 439 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 474 481 438 441 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;<italic>T</italic>m</sub>
###xml 497 498 453 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 492 499 452 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;<italic>T</italic>m</sub>
###xml 512 513 464 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 507 514 463 466 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;<italic>T</italic>m</sub>
###xml 566 567 514 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 567 568 515 516 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
DeltaTm values were taken from Table 1 of [86], Table 1 of [60], Table 2 of [87], Table 3 of [88], and Table II of [31]. DeltaTm values from [60,87,88] were averaged for each mutation. Those results then were averaged with the DeltaTm values from [31,86] to determine the DeltaTm values for given mutations. The normalized DeltaTm values were obtained by applying the equation normalized DeltaTm = (average DeltaTm values before normalization - MINDeltaTm)/(MAXDeltaTm - MINDeltaTm), with MINDeltaTm and MAXDeltaTm as the minimum and maximum values of averaged DeltaTm values in this dataset, respectively.
###end p 64
###begin title 65
Thermodynamic instability of SOD1 variants.
###end title 65
###begin p 66
###xml 134 135 126 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 156 157 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 157 158 145 146 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 237 238 217 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 247 248 223 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 248 249 224 225 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
The instability values for SOD1 variants were obtained from the equation normalized instability = 1 - average of normalized DeltaDeltaG and normalized DeltaTm for each mutation, so instability values are simply (1 - normalized DeltaDeltaG or DeltaTm), and larger values correlate to less stable variants.
###end p 66
###begin p 67
The normalized aggregation propensity and instability for each variant were summed and normalized to the range from 0 to 1 to consider the two factors together.
###end p 67
###begin title 68
Supporting Information
###end title 68
###begin title 69
Translation of the Abstract into Chinese by Qi Wang
###end title 69
###begin p 70
(62 KB PDF)
###end p 70
###begin p 71
Click here for additional data file.
###end p 71
###begin title 72
Lack of Correlation between SOD1 Aggregation Propensity and SOD1 Instability
###end title 72
###begin p 73
###xml 61 70 61 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g003">Figures 3</xref>
###xml 75 76 75 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060170-g004">4</xref>
The same dataset for fALS-associated SOD1 mutations shown in Figures 3 and 4 were considered. The predicted aggregation propensities and instabilities from 28 different fALS-causing SOD1 mutations were plotted using the software SigmaPlot 9.0 (Systat Software, Inc.).
###end p 73
###begin p 74
(213 KB AI).
###end p 74
###begin p 75
Click here for additional data file.
###end p 75
###begin title 76
###xml 143 151 <span type="species:ncbi:9606">Patients</span>
Little or No Correlation between SOD1 Aggregation Propensity, SOD1 Instability, or the Sum of Aggregation Propensity and Instability with fALS Patients' Age of Onset
###end title 76
###begin p 77
###xml 147 155 <span type="species:ncbi:9606">patients</span>
###xml 258 266 <span type="species:ncbi:9606">patients</span>
###xml 393 401 <span type="species:ncbi:9606">patients</span>
###xml 532 540 <span type="species:ncbi:9606">patients</span>
###xml 695 703 <span type="species:ncbi:9606">patients</span>
###xml 1054 1062 <span type="species:ncbi:9606">patients</span>
The relationship between SOD1 aggregation propensity (A, D), instability (B, E), or sum of aggregation propensity and instability (C, F) with fALS patients' age of onset are presented. The linear regressions presented in (A-C) were weighted by the number of patients for each mutation using SPSS version 15.0 (SPSS, Inc.). The correlation between the size of each data point and the number of patients for (A-C) is shown as an inset in (C). The linear regressions presented in (D-F) were treated equally regardless of the number of patients for each mutation (unweighted) using the software SigmaPlot 9.0 (Systat Software, Inc.). The age of onset data presented in these six graphs are from 649 patients with 29 different fALS-causing SOD1 mutations with reported stability values. Aggregation propensity, instability, and sum of aggregation propensity and instability were obtained as described in the Materials and Methods section. Aggregation propensity, instability, or sum of aggregation propensity and instability has little or no correlation with patients' age of onset.
###end p 77
###begin p 78
(261 KB AI).
###end p 78
###begin p 79
Click here for additional data file.
###end p 79
###begin p 80
###xml 394 402 <span type="species:ncbi:9606">patients</span>
###xml 421 428 <span type="species:ncbi:9606">patient</span>
###xml 632 639 <span type="species:ncbi:9606">patient</span>
###xml 704 712 <span type="species:ncbi:9606">patients</span>
We thank Professor F. Chiti for help with understanding the application of the Chiti-Dobson equation. We thank Drs. G. A. Petsko, D. Ringe, M. Rosbash, E. Marder, R. Finke, N. Bonini, and I. Epstein, the entire Agar laboratory, and A. Morris for comments on the manuscript. We thank J. Lani from Statistics Solutions for advice on statistical analysis. We especially thank the neurologists and patients worldwide for the patient outcome data used in this study, while noting that improving upon this study and extending this study to sporadic disease requires that physicians begin to include epidemiological information, including patient lifestyle and palliative care for all neurodegenerative disease patients.
###end p 80
###begin title 81
Abbreviations
###end title 81
###begin p 82
amyotrophic lateral sclerosis
###end p 82
###begin p 83
familial ALS
###end p 83
###begin p 84
mutant
###end p 84
###begin p 85
sporadic ALS
###end p 85
###begin p 86
Cu/Zn-superoxide dismutase
###end p 86
###begin p 87
wild-type
###end p 87
###begin title 88
References
###end title 88
###begin article-title 89
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
###end article-title 89
###begin article-title 90
Amyotrophic lateral sclerosis
###end article-title 90
###begin article-title 91
Genetics of familial amyotrophic lateral sclerosis
###end article-title 91
###begin article-title 92
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis
###end article-title 92
###begin article-title 93
Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene
###end article-title 93
###begin article-title 94
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury
###end article-title 94
###begin article-title 95
###xml 29 33 <span type="species:ncbi:10090">mice</span>
###xml 49 54 <span type="species:ncbi:9606">human</span>
Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation
###end article-title 95
###begin article-title 96
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 38 44 <span type="species:ncbi:10090">murine</span>
Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis
###end article-title 96
###begin article-title 97
An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria
###end article-title 97
###begin article-title 98
Mutant SOD1 instability: implications for toxicity in amyotrophic lateral sclerosis
###end article-title 98
###begin article-title 99
Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis
###end article-title 99
###begin article-title 100
###xml 127 132 <span type="species:ncbi:9606">human</span>
Familial amyotrophic lateral sclerosis-associated mutations decrease the thermal stability of distinctly metallated species of human copper/zinc superoxide dismutase
###end article-title 100
###begin article-title 101
Dimer destabilization in superoxide dismutase may result in disease-causing properties: structures of motor neuron disease mutants
###end article-title 101
###begin article-title 102
Common denominator of Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis: decreased stability of the apo state
###end article-title 102
###begin article-title 103
Systematically perturbed folding patterns of amyotrophic lateral sclerosis (ALS)-associated SOD1 mutants
###end article-title 103
###begin article-title 104
Aberrantly increased hydrophobicity shared by mutants of Cu,Zn-superoxide dismutase in familial amyotrophic lateral sclerosis
###end article-title 104
###begin article-title 105
SOD1 aggregates in ALS: cause, correlate or consequence
###end article-title 105
###begin article-title 106
How do ALS-associated mutations in superoxide dismutase 1 promote aggregation of the protein
###end article-title 106
###begin article-title 107
Do posttranslational modifications of CuZnSOD lead to sporadic amyotrophic lateral sclerosis
###end article-title 107
###begin article-title 108
Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis
###end article-title 108
###begin article-title 109
Familial amyotrophic lateral sclerosis mutants of copper/zinc superoxide dismutase are susceptible to disulfide reduction
###end article-title 109
###begin article-title 110
Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial amyotrophic lateral sclerosis
###end article-title 110
###begin article-title 111
Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria
###end article-title 111
###begin article-title 112
###xml 147 151 <span type="species:ncbi:10090">mice</span>
Disulfide cross-linked protein represents a significant fraction of ALS-associated Cu, Zn-superoxide dismutase aggregates in spinal cords of model mice
###end article-title 112
###begin article-title 113
Relevance of oxidative injury in the pathogenesis of motor neuron diseases
###end article-title 113
###begin article-title 114
Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite
###end article-title 114
###begin article-title 115
###xml 46 51 <span type="species:ncbi:9606">human</span>
Structural characterization of zinc-deficient human superoxide dismutase and implications for ALS
###end article-title 115
###begin article-title 116
Amyloid-like filaments and water-filled nanotubes formed by SOD1 mutant proteins linked to familial ALS
###end article-title 116
###begin article-title 117
###xml 52 57 <span type="species:ncbi:9606">human</span>
The structure of holo and metal-deficient wild-type human Cu, Zn superoxide dismutase and its relevance to familial amyotrophic lateral sclerosis
###end article-title 117
###begin article-title 118
###xml 45 50 <span type="species:ncbi:9606">human</span>
The unusually stable quaternary structure of human Cu,Zn-superoxide dismutase 1 is controlled by both metal occupancy and disulfide status
###end article-title 118
###begin article-title 119
Amyotrophic lateral sclerosis mutations have the greatest destabilizing effect on the apo- and reduced form of SOD1, leading to unfolding and oxidative aggregation
###end article-title 119
###begin article-title 120
Metal-free superoxide dismutase forms soluble oligomers under physiological conditions: a possible general mechanism for familial ALS
###end article-title 120
###begin article-title 121
Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant
###end article-title 121
###begin article-title 122
ALS, SOD and peroxynitrite
###end article-title 122
###begin article-title 123
Superoxide dismutase catalyzes nitration of tyrosines by peroxynitrite in the rod and head domains of neurofilament-L
###end article-title 123
###begin article-title 124
Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis
###end article-title 124
###begin article-title 125
###xml 104 105 104 105 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 103 105 103 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>m</sub></italic>
###xml 176 177 176 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 175 177 175 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K<sub>m</sub></italic>
A familial amyotrophic lateral sclerosis-associated A4V Cu, Zn-superoxide dismutase mutant has a lower Km for hydrogen peroxide. Correlation between clinical severity and the Km value
###end article-title 125
###begin article-title 126
The proteasome in neurodegeneration
###end article-title 126
###begin article-title 127
###xml 62 67 <span type="species:ncbi:10090">mouse</span>
Focal dysfunction of the proteasome: a pathogenic factor in a mouse model of amyotrophic lateral sclerosis
###end article-title 127
###begin article-title 128
Failure of protein quality control in amyotrophic lateral sclerosis
###end article-title 128
###begin article-title 129
Cytoskeletal abnormalities in motor neuron disease. An immunocytochemical study
###end article-title 129
###begin article-title 130
Mutations in dynein link motor neuron degeneration to defects in retrograde transport
###end article-title 130
###begin article-title 131
###xml 43 48 <span type="species:ncbi:10090">mouse</span>
Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis
###end article-title 131
###begin article-title 132
Analysis of the cytosolic proteome in a cell culture model of familial amyotrophic lateral sclerosis reveals alterations to the proteasome, antioxidant defenses, and nitric oxide synthetic pathways
###end article-title 132
###begin article-title 133
Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis
###end article-title 133
###begin article-title 134
Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis
###end article-title 134
###begin article-title 135
Inhibition of chaperone activity is a shared property of several Cu,Zn-superoxide dismutase mutants that cause amyotrophic lateral sclerosis
###end article-title 135
###begin article-title 136
Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death
###end article-title 136
###begin article-title 137
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1
###end article-title 137
###begin article-title 138
###xml 75 90 <span type="species:ncbi:10090">transgenic mice</span>
CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations
###end article-title 138
###begin article-title 139
###xml 107 111 <span type="species:ncbi:10090">mice</span>
Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1
###end article-title 139
###begin article-title 140
Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria
###end article-title 140
###begin article-title 141
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis
###end article-title 141
###begin article-title 142
###xml 53 59 <span type="species:ncbi:10090">murine</span>
###xml 80 85 <span type="species:ncbi:9606">human</span>
Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis
###end article-title 142
###begin article-title 143
###xml 52 67 <span type="species:ncbi:10090">transgenic mice</span>
The Golgi apparatus of spinal cord motor neurons in transgenic mice expressing mutant Cu,Zn superoxide dismutase becomes fragmented in early, preclinical stages of the disease
###end article-title 143
###begin article-title 144
High molecular weight complexes of mutant superoxide dismutase 1: age-dependent and tissue-specific accumulation
###end article-title 144
###begin article-title 145
Mapping superoxide dismutase 1 domains of non-native interaction: roles of intra- and intermolecular disulfide bonding in aggregation
###end article-title 145
###begin article-title 146
Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS
###end article-title 146
###begin article-title 147
###xml 44 59 <span type="species:ncbi:10090">transgenic mice</span>
Copper-binding-site-null SOD1 causes ALS in transgenic mice: aggregates of non-native SOD1 delineate a common feature
###end article-title 147
###begin article-title 148
Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis show enhanced formation of aggregates in vitro
###end article-title 148
###begin article-title 149
###xml 91 95 <span type="species:ncbi:10090">Mice</span>
Detergent-insoluble Aggregates Associated with Amyotrophic Lateral Sclerosis in Transgenic Mice Contain Primarily Full-length, Unmodified Superoxide Dismutase-1
###end article-title 149
###begin article-title 150
SOD1 and Amyotrophic Lateral Sclerosis: Mutations and Oligomerization
###end article-title 150
###begin article-title 151
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials
###end article-title 151
###begin article-title 152
Amyotrophic lateral sclerosis: early predictors of prolonged survival
###end article-title 152
###begin article-title 153
Predictability of disease progression in amyotrophic lateral sclerosis
###end article-title 153
###begin article-title 154
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing
###end article-title 154
###begin article-title 155
Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis
###end article-title 155
###begin article-title 156
Amyotrophic lateral sclerosis-associated copper/zinc superoxide dismutase mutations preferentially reduce the repulsive charge of the proteins
###end article-title 156
###begin article-title 157
Rationalization of the effects of mutations on peptide and protein aggregation rates
###end article-title 157
###begin article-title 158
Computational models for the prediction of polypeptide aggregation propensity
###end article-title 158
###begin article-title 159
Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins
###end article-title 159
###begin article-title 160
Systematic in vivo analysis of the intrinsic determinants of amyloid beta pathogenicity
###end article-title 160
###begin article-title 161
Prediction of the absolute aggregation rates of amyloidogenic polypeptide chains
###end article-title 161
###begin article-title 162
Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences
###end article-title 162
###begin article-title 163
Prediction of "hot spots" of aggregation in disease-linked polypeptides
###end article-title 163
###begin article-title 164
Lifetime occupation, education, smoking, and risk of ALS
###end article-title 164
###begin article-title 165
Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption
###end article-title 165
###begin article-title 166
Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. II. Diet
###end article-title 166
###begin article-title 167
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Nutritional status is a prognostic factor for survival in ALS patients
###end article-title 167
###begin article-title 168
###xml 59 67 <span type="species:ncbi:9606">patients</span>
[A comparative study between amyotrophic lateral sclerosis patients with and without mechanical ventilation]
###end article-title 168
###begin article-title 169
Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats
###end article-title 169
###begin article-title 170
###xml 42 47 <span type="species:ncbi:9606">human</span>
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis
###end article-title 170
###begin article-title 171
Myoglobin forms amyloid fibrils by association of unfolded polypeptide segments
###end article-title 171
###begin article-title 172
Familial Alzheimer's disease mutations alter the stability of the amyloid beta-protein monomer folding nucleus
###end article-title 172
###begin article-title 173
Misfolding of amyloidogenic proteins at membrane surfaces: the impact of macromolecular crowding
###end article-title 173
###begin article-title 174
Destabilization of apoprotein is insufficient to explain Cu,Zn-superoxide dismutase-linked ALS pathogenesis
###end article-title 174
###begin article-title 175
Calorimetric analysis of thermodynamic stability and aggregation for apo and holo amyotrophic lateral sclerosis-associated Gly-93 mutants of superoxide dismutase
###end article-title 175
###begin article-title 176
Equilibrium thermodynamic analysis of amyotrophic lateral sclerosis-associated mutant apo Cu,Zn superoxide dismutases
###end article-title 176
###begin article-title 177
Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity
###end article-title 177
###begin article-title 178
Interpreting the aggregation kinetics of amyloid peptides
###end article-title 178
###begin article-title 179
Alternative conformations of amyloidogenic proteins govern their behavior
###end article-title 179
###begin article-title 180
Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates
###end article-title 180
###begin article-title 181
###xml 15 20 <span type="species:ncbi:9606">human</span>
ALS mutants of human superoxide dismutase form fibrous aggregates via framework destabilization
###end article-title 181
###begin article-title 182
Evidence for a mechanism of amyloid formation involving molecular reorganisation within native-like precursor aggregates
###end article-title 182
###begin article-title 183
Mechanism and thermodynamics of guanidinium chloride-induced denaturation of ALS-associated mutant Cu,Zn superoxide dismutases
###end article-title 183
###begin article-title 184
Local unfolding in a destabilized, pathogenic variant of superoxide dismutase 1 observed with H/D exchange and mass spectrometry
###end article-title 184
###begin article-title 185
Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases
###end article-title 185
###begin article-title 186
Age at onset in sod1-mediated amyotrophic lateral sclerosis shows familiality
###end article-title 186
###begin article-title 187
Nonideality and the nucleation of sickle hemoglobin
###end article-title 187
###begin article-title 188
Mutagenic analysis of the nucleation propensity of oxidized Alzheimer's beta-amyloid peptide
###end article-title 188
###begin article-title 189
Fitting neurological protein aggregation kinetic data via a 2-step, minimal/"Ockham's razor" model: the Finke-Watzky mechanism of nucleation followed by autocatalytic surface growth
###end article-title 189
###begin article-title 190
The D90A mutation results in a polymorphism of Cu,Zn superoxide dismutase that is prevalent in northern Sweden and Finland
###end article-title 190
###begin article-title 191
D90A heterozygosity in the SOD1 gene is associated with familial and apparently sporadic amyotrophic lateral sclerosis
###end article-title 191
###begin article-title 192
Kinetics and thermodynamics of amyloid assembly using a high-performance liquid chromatography-based sedimentation assay
###end article-title 192
###begin article-title 193
Mutation of SOD1 in ALS: a gain of a loss of function
###end article-title 193
###begin article-title 194
Opinion: what is the role of protein aggregation in neurodegeneration
###end article-title 194
###begin article-title 195
Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders
###end article-title 195
###begin article-title 196
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases
###end article-title 196
###begin article-title 197
Tryptophan 32 potentiates aggregation and cytotoxicity of a copper/zinc superoxide dismutase mutant associated with familial amyotrophic lateral sclerosis
###end article-title 197
###begin article-title 198
Heterodimer formation of wild-type and amyotrophic lateral sclerosis-causing mutant Cu/Zn-Superoxide dismutase induces toxicity independent of protein aggregation
###end article-title 198
###begin article-title 199
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
###end article-title 199
###begin article-title 200
Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution
###end article-title 200
###begin article-title 201
Intense superoxide dismutase-1 immunoreactivity in intracytoplasmic hyaline inclusions of familial amyotrophic lateral sclerosis with posterior column involvement
###end article-title 201
###begin article-title 202
###xml 82 90 <span type="species:ncbi:9606">patients</span>
Immunohistochemical study on superoxide dismutases in spinal cords from autopsied patients with amyotrophic lateral sclerosis
###end article-title 202
###begin article-title 203
Protein aggregation in motor neurone disorders
###end article-title 203
###begin article-title 204
###xml 54 69 <span type="species:ncbi:10090">transgenic mice</span>
Fibrillar inclusions and motor neuron degeneration in transgenic mice expressing superoxide dismutase 1 with a disrupted copper-binding site
###end article-title 204
###begin article-title 205
ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions
###end article-title 205
###begin article-title 206
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse motor neuron disease caused by truncated SOD1 with or without C-terminal modification
###end article-title 206
###begin article-title 207
Minute quantities of misfolded mutant superoxide dismutase-1 cause amyotrophic lateral sclerosis
###end article-title 207
###begin article-title 208
###xml 62 67 <span type="species:ncbi:10090">mouse</span>
Neuroprotective effect of oxidized galectin-1 in a transgenic mouse model of amyotrophic lateral sclerosis
###end article-title 208
###begin article-title 209
###xml 122 137 <span type="species:ncbi:10090">transgenic mice</span>
Mutant SOD1 linked to familial amyotrophic lateral sclerosis, but not wild-type SOD1, induces ER stress in COS7 cells and transgenic mice
###end article-title 209
###begin article-title 210
Inclusions of amyotrophic lateral sclerosis-linked superoxide dismutase in ventral horns, liver, and kidney
###end article-title 210
###begin article-title 211
###xml 113 119 <span type="species:ncbi:10090">murine</span>
Soluble misfolded subfractions of mutant superoxide dismutase-1s are enriched in spinal cords throughout life in murine ALS models
###end article-title 211
###begin article-title 212
###xml 24 28 <span type="species:ncbi:10090">mice</span>
Motor neuron disease in mice expressing the wild type-like D90A mutant superoxide dismutase-1
###end article-title 212
###begin article-title 213
Somatodendritic accumulation of misfolded SOD1-L126Z in motor neurons mediates degeneration: alphaB-crystallin modulates aggregation
###end article-title 213
###begin article-title 214
###xml 22 27 <span type="species:ncbi:10090">mouse</span>
The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies
###end article-title 214
###begin article-title 215
###xml 0 4 <span type="species:ncbi:10116">Rats</span>
###xml 16 21 <span type="species:ncbi:9606">human</span>
Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease
###end article-title 215
###begin article-title 216
###xml 62 65 <span type="species:ncbi:10116">rat</span>
Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS)
###end article-title 216
###begin article-title 217
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis
###end article-title 217
###begin article-title 218
Mutant Cu/Zn-superoxide dismutase proteins have altered solubility and interact with heat shock/stress proteins in models of amyotrophic lateral sclerosis
###end article-title 218
###begin article-title 219
Coincident thresholds of mutant protein for paralytic disease and protein aggregation caused by restrictively expressed superoxide dismutase cDNA
###end article-title 219
###begin article-title 220
Survival analysis (or time to an event analysis), and the Cox regression model-methods for longitudinal psychiatric research
###end article-title 220
###begin article-title 221
Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases
###end article-title 221
###begin article-title 222
Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide. An experimental support for the key role of the phenylalanine residue in amyloid formation
###end article-title 222
###begin article-title 223
S20G mutant amylin exhibits increased in vitro amyloidogenicity and increased intracellular cytotoxicity compared to wild-type amylin
###end article-title 223
###begin article-title 224
Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126
###end article-title 224
###begin article-title 225
###xml 163 164 163 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
The Val-210-Ile pathogenic Creutzfeldt-Jakob disease mutation increases both the helical and aggregation propensities of a sequence corresponding to helix-3 of PrPC
###end article-title 225
###begin article-title 226
Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy
###end article-title 226
###begin article-title 227
A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly
###end article-title 227
###begin article-title 228
Pathogenic effects of D23N Iowa mutant amyloid beta -protein
###end article-title 228
###begin article-title 229
###xml 118 123 <span type="species:ncbi:9606">human</span>
Substitutions at codon 22 of Alzheimer's Abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells
###end article-title 229
###begin article-title 230
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation
###end article-title 230
###begin article-title 231
###xml 59 64 <span type="species:ncbi:9606">human</span>
Point substitution in the central hydrophobic cluster of a human beta-amyloid congener disrupts peptide folding and abolishes plaque competence
###end article-title 231
###begin article-title 232
Tau polymerization: role of the amino terminus
###end article-title 232
###begin article-title 233
Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias
###end article-title 233
###begin article-title 234
In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants
###end article-title 234
###begin article-title 235
Accelerated filament formation from tau protein with specific FTDP-17 missense mutations
###end article-title 235
###begin article-title 236
Structure, stability, and aggregation of paired helical filaments from tau protein and FTDP-17 mutants probed by tryptophan scanning mutagenesis
###end article-title 236
###begin article-title 237
X-ray diffraction and far-UV CD studies of filaments formed by a leucine-rich repeat peptide: structural similarity to the amyloid fibrils of prions and Alzheimer's disease beta-protein
###end article-title 237
###begin article-title 238
Induction of beta-sheet structure in amyloidogenic peptides by neutralization of aspartate: a model for amyloid nucleation
###end article-title 238
###begin article-title 239
###xml 83 88 <span type="species:ncbi:9606">human</span>
Activity, folding, misfolding, and aggregation in vitro of the naturally occurring human tissue factor mutant R200W
###end article-title 239
###begin article-title 240
D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis
###end article-title 240
###begin article-title 241
###xml 84 89 <span type="species:ncbi:9606">human</span>
Differences in aggregation properties of three site-specific mutants of recombinant human stefin B
###end article-title 241
###begin article-title 242
###xml 114 119 <span type="species:ncbi:9606">human</span>
A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein
###end article-title 242
###begin article-title 243
Glycine residues appear to be evolutionarily conserved for their ability to inhibit aggregation
###end article-title 243
###begin article-title 244
Rapid disease progression correlates with instability of mutant SOD1 in familial ALS
###end article-title 244
###begin article-title 245
A4T mutation in the SOD1 gene causing familial amyotrophic lateral sclerosis
###end article-title 245
###begin article-title 246
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Prognosis in familial amyotrophic lateral sclerosis: progression and survival in patients with Glu100Gly and Ala4Val mutations in Cu,Zn superoxide dismutase
###end article-title 246
###begin article-title 247
A novel mutation in Cu/Zn superoxide dismutase gene in Japanese familial amyotrophic lateral sclerosis
###end article-title 247
###begin article-title 248
Limited corticospinal tract involvement in amyotrophic lateral sclerosis subjects with the A4V mutation in the copper/zinc superoxide dismutase gene
###end article-title 248
###begin article-title 249
A frequent Ala 4 to Val superoxide dismutase-1 mutation is associated with a rapidly progressive familial amyotrophic lateral sclerosis
###end article-title 249
###begin article-title 250
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia
###end article-title 250
###begin article-title 251
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Superoxide dismutase gene mutations in Italian patients with familial and sporadic amyotrophic lateral sclerosis: identification of three novel missense mutations
###end article-title 251
###begin article-title 252
Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes
###end article-title 252
###begin article-title 253
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Corticomotoneuronal dysfunction in ALS patients with different SOD1 mutations
###end article-title 253
###begin article-title 254
A novel mutation (Cys6Gly) in the Cu/Zn superoxide dismutase gene associated with rapidly progressive familial amyotrophic lateral sclerosis
###end article-title 254
###begin article-title 255
A novel two-base mutation in the Cu/Zn superoxide dismutase gene associated with familial amyotrophic lateral sclerosis in Japan
###end article-title 255
###begin article-title 256
###xml 45 46 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
A new variant Cu/Zn superoxide dismutase (Val7-->Glu) deduced from lymphocyte mRNA sequences from Japanese patients with familial amyotrophic lateral sclerosis
###end article-title 256
###begin article-title 257
A novel SOD1 mutation in an Austrian family with amyotrophic lateral sclerosis
###end article-title 257
###begin article-title 258
A novel SOD1 gene mutation in a Korean family with amyotrophic lateral sclerosis
###end article-title 258
###begin article-title 259
###xml 26 33 <span type="species:ncbi:9606">patient</span>
A SOD1 gene mutation in a patient with slowly progressing familial ALS
###end article-title 259
###begin article-title 260
SOD1 mutations in amyotrophic lateral sclerosis. Results from a multicenter Italian study
###end article-title 260
###begin article-title 261
Genetics of ALS in Italian families
###end article-title 261
###begin article-title 262
Clinical characteristics of familial amyotrophic lateral sclerosis with a Phe20Cys mutation in the SOD1 gene in a Korean family
###end article-title 262
###begin article-title 263
[Superoxyde dismutase 1 gene abnormalities in familial amyotrophic lateral sclerosis: phenotype/genotype correlations. The French experience and review of the literature]
###end article-title 263
###begin article-title 264
Genetics of familial ALS and consequences for diagnosis. French ALS Research Group
###end article-title 264
###begin article-title 265
Familial amyotrophic lateral sclerosis with a point mutation (G37R) of the superoxide dismutase 1 gene: a clinicopathological study
###end article-title 265
###begin article-title 266
Mutational analysis of the Cu/Zn superoxide dismutase gene in a Catalan ALS population: should all sporadic ALS cases also be screened for SOD1
###end article-title 266
###begin article-title 267
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Molecular analysis of the superoxide dismutase 1 gene in Spanish patients with sporadic or familial amyotrophic lateral sclerosis
###end article-title 267
###begin article-title 268
The G93C mutation in superoxide dismutase 1: clinicopathologic phenotype and prognosis
###end article-title 268
###begin article-title 269
SOD1 missense mutation in an Italian family with ALS
###end article-title 269
###begin article-title 270
Clinical and pathological studies of familial amyotrophic lateral sclerosis (FALS) with SOD1 H46R mutation in large Japanese families
###end article-title 270
###begin article-title 271
Familial amyotrophic lateral sclerosis with His46Arg mutation in Cu/Zn superoxide dismutase presenting characteristic clinical features and Lewy body-like hyaline inclusions
###end article-title 271
###begin article-title 272
Clinical features and neuropathological findings of familial amyotrophic lateral sclerosis with a His46Arg mutation in Cu/Zn superoxide dismutase
###end article-title 272
###begin article-title 273
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Molecular analyses of the Cu/Zn superoxide dismutase gene in patients with familial amyotrophic lateral sclerosis (ALS) in Japan
###end article-title 273
###begin article-title 274
Slowly progressing amyotrophic lateral sclerosis caused by H46R SOD1 mutation
###end article-title 274
###begin article-title 275
###xml 65 72 <span type="species:ncbi:9606">patient</span>
Familial amyotrophic lateral sclerosis. Molecular pathology of a patient with a SOD1 mutation
###end article-title 275
###begin article-title 276
Clinical and functional investigation of 10 missense mutations and a novel frameshift insertion mutation of the gene for copper-zinc superoxide dismutase in UK families with amyotrophic lateral sclerosis
###end article-title 276
###begin article-title 277
Clinicopathological phenotype of ALS with a novel G72C SOD1 gene mutation mimicking a myopathy
###end article-title 277
###begin article-title 278
Familial ALS is associated with mutations in all exons of SOD1: a novel mutation in exon 3 (Gly72Ser)
###end article-title 278
###begin article-title 279
A novel exon 3 mutation (D76V) in the SOD1 gene associated with slowly progressive ALS
###end article-title 279
###begin article-title 280
###xml 18 26 <span type="species:ncbi:9606">patients</span>
Clustering of ALS patients in central Italy due to the occurrence of the L84F SOD1 gene mutation
###end article-title 280
###begin article-title 281
Mutations in all five exons of SOD-1 may cause ALS
###end article-title 281
###begin article-title 282
###xml 53 61 <span type="species:ncbi:9606">patients</span>
SOD1 activity and protective factors in familial ALS patients with L84F SOD1 mutation
###end article-title 282
###begin article-title 283
[Familial amyotrophic lateral sclerosis showing variable clinical courses with (Leu84-->Val) mutation of Cu/Zn superoxide dismutase]
###end article-title 283
###begin article-title 284
Novel SOD1 N86K mutation is associated with a severe phenotype in familial ALS
###end article-title 284
###begin article-title 285
[On intra-familial clinical diversities of a familial amyotrophic lateral sclerosis with a point mutation of Cu/Zn superoxide dismutase (Asn 86-Ser)]
###end article-title 285
###begin article-title 286
A rare Cu/Zn superoxide dismutase mutation causing familial amyotrophic lateral sclerosis with variable age of onset, incomplete penetrance and a sensory neuropathy
###end article-title 286
###begin article-title 287
Coexistence of dominant and recessive familial amyotrophic lateral sclerosis with the D90A Cu,Zn superoxide dismutase mutation within the same country
###end article-title 287
###begin article-title 288
A novel mutation Asp90Val in the SOD1 gene associated with Japanese familial ALS
###end article-title 288
###begin article-title 289
###xml 107 115 <span type="species:ncbi:9606">patients</span>
Identification of two novel mutations and a new polymorphism in the gene for Cu/Zn superoxide dismutase in patients with amyotrophic lateral sclerosis
###end article-title 289
###begin article-title 290
Prominent sensory and autonomic disturbances in familial amyotrophic lateral sclerosis with a Gly93Ser mutation in the SOD1 gene
###end article-title 290
###begin article-title 291
Anticipation in familial amyotrophic lateral sclerosis with SOD1-G93S mutation
###end article-title 291
###begin article-title 292
Three novel mutations and two variants in the gene for Cu/Zn superoxide dismutase in familial amyotrophic lateral sclerosis
###end article-title 292
###begin article-title 293
Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes
###end article-title 293
###begin article-title 294
Progressive muscular atrophy variant of familial amyotrophic lateral sclerosis (PMA/ALS)
###end article-title 294
###begin article-title 295
Difficulties in distinguishing sporadic from familial amyotrophic lateral sclerosis
###end article-title 295
###begin article-title 296
Clinical characteristics of SOD1 gene mutations in UK families with ALS
###end article-title 296
###begin article-title 297
Identification of two novel mutations in the Cu/Zn superoxide dismutase gene with familial amyotrophic lateral sclerosis: mass spectrometric and genomic analyses
###end article-title 297
###begin article-title 298
Familial amyotrophic lateral sclerosis with bulbar onset and a novel Asp101Tyr Cu/Zn superoxide dismutase gene mutation
###end article-title 298
###begin article-title 299
Clinical and molecular analysis of neurodegenerative diseases
###end article-title 299
###begin article-title 300
A rare Cu/Zn superoxide dismutase mutation causing familial amyotrophic lateral sclerosis with variable age of onset and incomplete penetrance in China
###end article-title 300
###begin article-title 301
A novel mutation of SOD-1 (Gly 108 Val) in familial amyotrophic lateral sclerosis
###end article-title 301
###begin article-title 302
SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis
###end article-title 302
###begin article-title 303
###xml 69 76 <span type="species:ncbi:9606">patient</span>
Accumulation of neurofilaments and SOD1-immunoreactive products in a patient with familial amyotrophic lateral sclerosis with I113T SOD1 mutation
###end article-title 303
###begin article-title 304
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Superoxide dismutase mutations in an unselected cohort of Scottish amyotrophic lateral sclerosis patients
###end article-title 304
###begin article-title 305
Amyotrophic lateral sclerosis associated with genetic abnormalities in the gene encoding Cu/Zn superoxide dismutase: molecular pathology of five new cases, and comparison with previous reports and 73 sporadic cases of ALS
###end article-title 305
###begin article-title 306
"Sporadic" motoneuron disease due to familial SOD1 mutation with low penetrance
###end article-title 306
###begin article-title 307
Autosomal dominant amyotrophic lateral sclerosis: a novel mutation in the Cu/Zn superoxide dismutase-1 gene
###end article-title 307
###begin article-title 308
Two novel mutations in the gene for copper zinc superoxide dismutase in UK families with amyotrophic lateral sclerosis
###end article-title 308
###begin article-title 309
Familial amyotrophic lateral sclerosis with a novel Leu126Ser mutation in the copper/zinc superoxide dismutase gene showing mild clinical features and lewy body-like hyaline inclusions
###end article-title 309
###begin article-title 310
A novel SOD1 gene mutation in familial ALS with low penetrance in females
###end article-title 310
###begin article-title 311
###xml 84 91 <span type="species:ncbi:9606">patient</span>
A novel missense point mutation (S134N) of the Cu/Zn superoxide dismutase gene in a patient with familial motor neuron disease
###end article-title 311
###begin article-title 312
A novel exon 5 mutation (N139H) in the SOD1 gene in a Spanish family associated with incomplete penetrance
###end article-title 312
###begin article-title 313
Identification of a novel mutation in Cu/Zn superoxide dismutase gene associated with familial amyotrophic lateral sclerosis
###end article-title 313
###begin article-title 314
ALS with variable phenotypes in a six-generation family caused by Leu144Phe mutation in the SOD1 gene
###end article-title 314
###begin article-title 315
An Italian dominant FALS Leu144Phe SOD1 mutation: genotype-phenotype correlation
###end article-title 315
###begin article-title 316
[Different clinical phenotypes of siblings with familial amyotrophic lateral sclerosis showing Cys146Arg point mutation of superoxide dismutase 1 gene]
###end article-title 316
###begin article-title 317
Clinical phenotypes of a large Chinese multigenerational kindred with autosomal dominant familial ALS due to Ile149Thr SOD1 gene mutation
###end article-title 317
###begin article-title 318
Superoxide dismutase 1: identification of a novel mutation in a case of familial amyotrophic lateral sclerosis
###end article-title 318
###begin p 319
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. JNA and NYRA conceived the hypotheses. QW and JNA designed the analysis. QW, JLJ, and JNA performed the analysis. QW and JNA wrote the paper.
###end p 319
###begin p 320
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. This work was made possible by award W81XWH-04-0158 from the Department of Defense and grant 1392 from the ALS Association. NYRA was supported by a research award from the American Brain Tumor Association and a research grant from the Brain Science Foundation.
###end p 320
###begin p 321
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 321

